C C191385 Symptoms and Signs Guillain-Barré syndrome C191402 Physical Examination C116345 Guillain-Barre Syndrome Guillain Barre Syndrome || Guillain Barré Syndrome || Guillain-Barré Syndrome A rapidly progressive autoimmune disorder of the peripheral nervous system characterized by limb paresthesias, areflexia, and generalized muscle weakness or paralysis that often begins in the legs and spreads to the arms, torso, and face. C C191382 COVID-19 Diagnosis Multisystem inflammatory syndrome in adults (MIS-A) A patient aged greater than or equal to 21 y hospitalized for greater than or equal to 24 h, or with an illness resulting in death, who meets the following clinical and laboratory criteria. The patient should not have a more likely alternative diagnosis for the illness (e.g., bacterial sepsis, exacerbation of a chronic medical condition). I. Clinical Criteria: Subjective fever or documented fever (greater than or equal to 38.0 degrees C) for greater than or equal to 24 h prior to hospitalization or within the first 3 d of hospitalization* and at least 3 of the following clinical criteria occurring prior to hospitalization or within the first 3 d of hospitalization*. At least 1 must be a primary clinical criterion: A. Primary clinical criteria: 1. Severe cardiac illness includes myocarditis, pericarditis, coronary artery dilatation/aneurysm, or new-onset right or left ventricular dysfunction (LVEF <50%), 2nd/3rd degree AV block, or ventricular tachycardia. (Note: cardiac arrest alone does not meet this criterion) 2. Rash and nonpurulent conjunctivitis B. Secondary clinical criteria: 1. New-onset neurological signs and symptoms: includes encephalopathy in a patient without prior cognitive impairment, seizures, meningeal signs, or peripheral neuropathy (including Guillain-Barr� syndrome) 2. Shock or hypotension not attributable to medical therapy (e.g., sedation, renal replacement therapy) 3. Abdominal pain, vomiting, or diarrhea 4. Thrombocytopenia (platelet count <150,000/microliter) II. Laboratory evidence: The presence of laboratory evidence of inflammation and SARS-CoV-2 infection. A. Elevated levels of at least 2 of the following: C-reactive protein, ferritin, IL-6, erythrocyte sedimentation rate, procalcitonin B. A positive SARS-CoV-2 test for current or recent infection by RT-PCR, serology, or antigen detection NOTE: *These criteria must be met by the end of hospital day 3, where the date of hospital admission is hospital day 0. C178502 Multisystem Inflammatory Syndrome in Adults A rare syndrome found in adults with positive test results for SARS-CoV-2 by polymerase chain reaction or antibody assays indicating recent infection that is marked by cardiovascular, gastrointestinal, dermatologic, and neurologic symptoms without severe respiratory illness. The most common signs and symptoms that have been reported to date include fever, low blood pressure, abdominal pain, vomiting, diarrhea, neck pain, rash, chest pain, and tiredness not attributable to other infections. C C191383 COVID-19 Cardiovascular Complications Death due to acute MI C191397 Cardiovascular Mortality During Acute COVID-19 Infection Death by any cardiovascular mechanism (e.g., arrhythmia, sudden death, HF, stroke, pulmonary embolus, peripheral arterial disease) less than or equal to 30 d after a MI, related to the immediate consequences of the MI, such as progressive HF or recalcitrant arrhythmia in a patient with probable or confirmed acute COVID-19. There may be assessable mechanisms of cardiovascular death during this time period, but for simplicity, if the cardiovascular death occurs less than or equal to 30 d of the MI, it will be considered a death due to MI. C191480 Death due to Acute Myocardial Infarction Related to COVID-19 Death by any cardiovascular mechanism (e.g., arrhythmia, sudden death, heart failure (HF), stroke, pulmonary embolus, peripheral arterial disease) less than or equal to 30 days after a myocardial infarction (MI), related to the immediate consequences of the MI, such as progressive HF or recalcitrant arrhythmia in a patient with probable or confirmed acute COVID-19. C C191383 COVID-19 Cardiovascular Complications Sudden cardiac death C191397 Cardiovascular Mortality During Acute COVID-19 Infection Death that occurs unexpectedly and suddenly without ROSC in a patient with probable or confirmed acute COVID-19 and not within 30 d of an acute MI. Sudden cardiac death includes the following scenarios: a. Death witnessed and occurring without new or worsening symptoms b. Death witnessed within 60 min of the onset of new or worsening cardiac symptoms, unless the symptoms suggest acute MI c. Death witnessed and attributed to an identified arrhythmia (e.g., captured on an ECG recording, witnessed on a monitor, with asystole, pulseless electrical activity, ventricular tachycardia, or ventricular fibrillation, or unwitnessed but found on implantable cardioverter-defibrillator review) d. Unwitnessed death in a subject seen alive and clinically stable less than or equal to 24 h prior to being found dead without any evidence supporting a specific noncardiovascular cause of death (information regarding the patient's clinical status preceding death should be provided, if available) C191626 Sudden Cardiac Death Related to COVID-19 SCD Related to COVID-19 Sudden cardiac death in a patient with probable or confirmed acute COVID-19. C C191386 Diagnostic Procedures 0 0% C191503 Coronary Artery Disease Reporting and Data System Coronary CT Angiography Score 0 CAD-RADS CCTA Score 0 A Coronary Artery Disease Reporting and Data System Coronary CT Angiography Score that indicates that no plaque or stenosis is present. Absence of coronary artery disease. C C191386 Diagnostic Procedures 5 100% C191508 Coronary Artery Disease Reporting and Data System Coronary CT Angiography Score 5 CAD-RADS CCTA Score 5 A Coronary Artery Disease Reporting and Data System Coronary CT Angiography Score that indicates that total occlusion or subtotal occlusion is present.